Abbott Laboratories ABT

Key data

The business

Abbott sells four things under one roof. The growth engine is Medical Devices, and inside it the FreeStyle Libre, the coin-sized patch a diabetic sticks on the back of the upper arm to read blood sugar on a phone instead of pricking a finger. Then Diagnostics, the machines and tests that hospitals and labs run, now carrying Cologuard, the mail-in stool test for colon cancer that came with the Exact Sciences deal that closed in March. Then Nutrition, the Ensure and Pediasure and infant formula on the shelf. Then Established Pharmaceuticals, branded generic pills sold almost entirely in emerging markets. No single business is more than a third of sales, which is the whole point: when one stumbles, and one always does, the other three carry the quarter. The moat is a mix of installed base and switching cost. Once a hospital's labs run on Abbott analyzers, or a diabetic's phone talks to a Libre, ripping it out is a project nobody wants.

The numbers

The last five quarters show a business that was flat, then lurched on an acquisition.

The revenue line is real, up 13% year over year and a company record. The reported profit line falling while sales rose in prior quarters is the story. Abbott's Q2 adjusted EPS was $1.31, three cents past consensus, its usual small beat. The gap between adjusted EPS and GAAP is acquisition write-offs, and the lens table below shows why.

Ignore the 2024 spike. That $7.64 carries a large one-time gain, not operations, which is why 2025's $3.72 looks like a collapse and is not one. The clean read is 2023 to 2025: revenue back above the old peak as COVID testing finished washing out, operating margin recovering to about 18%.

Amortization up 57% is Exact Sciences hitting the income statement. That is the whole GAAP-versus-adjusted argument in one row: Abbott bought revenue and is now writing off the price of it against reported profit, so the two EPS numbers will not converge for years. On adjusted earnings you pay 20.6x trailing and 16.1x the 2028 consensus of $6.72, for a company that compounds adjusted EPS at low double digits with a fortress balance sheet, net debt at 2.8x EBITDA and interest covered twelve times. That is priced roughly fair, a slight discount to med-tech peers. The variant that matters: the market pays for a steady low-teens compounder, and the print that settles whether it is more is Diagnostics organic growth ex-COVID plus the Libre quarterly run-rate.

Management

Robert Ford, chairman and CEO, bought $2.0 million of stock in the open market in January, the rare signal a CEO cannot fake, then sold $46.2 million on August 25, plan status not disclosed in the filings pulled. Insiders across the company bought $4.4M and sold $47.3M over the year, so the net is a seller, weighted almost entirely to that one August day. Capital allocation is conservative and legible: long-term debt cut from $18.1B in 2021 to $12.9B in 2025, a Dividend King payout that never stops, and buybacks throttled way down, $0.9B last year against $3.8B in 2022, with the cash instead spent on Exact Sciences. The guidance record is the tell on the culture: four straight quarters of meeting or edging past its own adjusted number, never a miss, never a boast.

How it fails or surprises you

The Libre depends on one franchise. FreeStyle Libre carries device growth, and the device segment carries Abbott. If Dexcom's competition, pump integration, or a CMS reimbursement cut pushes Libre's quarterly growth below the mid-teens, the whole compounding story slows at once. The print: sensor sales growth falling under 15% for two quarters.

Cologuard and the pipeline re-rate it (right tail). The market pays for low-teens growth. If Cologuard cancer screening scales with Abbott's salesforce behind it, and Lingo, Volt PFA and the newer devices land, Diagnostics and Devices together push total growth toward mid-teens and the multiple follows. The market is not paying for this today. The print: Diagnostics organic growth back above high single digits ex-COVID in the first full year owning Exact Sciences.

The adjusted number could be a mirage. Amortization up 57% assumes the acquired intangibles throw off the revenue that justified the price. The infant-formula (NEC) litigation produced no new verdict or reserve in the Q2 10-Q filed July 28, but the docket is open and a large jury award would hit the reported line. The print: GAAP net income failing to climb back toward adjusted over the next four quarters.

Closing thoughts

The market prices Abbott correctly and the edge is small. The people on the other side, the index and quality funds, are paying for exactly what they see: four uncorrelated businesses, a dividend that has grown for decades, and a balance sheet that does not break. Your read only beats theirs if Libre and Cologuard drive mid-teens growth against their low-teens. The fatter tail is a modest upside, because the optionality is real and the downside is capped by that balance sheet. The genuine left tail is narrow: a Libre reimbursement shock or a runaway NEC verdict, either of which you would see coming in the numbers before it became permanent.

The bet is still that more people keep wearing the FreeStyle Libre on their arm and that Cologuard keeps selling, and that the boring giant keeps growing a little faster than the economy with no one piece blowing up. It breaks if device growth slips into the single digits while acquisition amortization keeps eating reported earnings. The one pair that tells you first is Medical Devices organic growth against the amortization line, quarter by quarter.